Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic | Public Health | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.239.150.57. Please contact the publisher to request reinstatement.
1.
American Hospital Association. AHA annual survey database. Accessed July 29, 2020. https://www.ahadata.com/aha-annual-survey-database
2.
US Centers for Medicare & Medicaid Services. FY 2020 final rule and correction notice data files. Accessed June 29, 2020. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2020-IPPS-Final-Rule-Home-Page-Items/FY2020-IPPS-Final-Rule-Data-Files
3.
US Centers for Medicare & Medicaid Services. 2019 POS file. Accessed September 4, 2020. https://www.cms.gov/research-statistics-data-systems/provider-services-current-files/2019-pos-file
4.
New York Times. Date, county, state, fips, cases, deaths. Accessed November 1, 2020. https://raw.githubusercontent.com/nytimes/covid-19-data/master/us-counties.csv
5.
National Quality Forum. Measure evaluation criteria and guidance for evaluating measures for endorsement. Accessed September 1, 2019. http://www.qualityforum.org/docs/measure_evaluation_criterias.aspx
6.
George  EI, Ročková  V, Rosenbaum  PR, Satopää  VA, Silber  JH.  Mortality rate estimation and standardization for public reporting: Medicare’s Hospital Compare.   J Am Stat Assoc. 2017;112:519, 933-947. doi:10.1080/01621459.2016.1276021 Google ScholarCrossref
7.
Silber  JH, Rosenbaum  PR, Brachet  TJ,  et al.  The Hospital Compare mortality model and the volume-outcome relationship.   Health Serv Res. 2010;45(5 Pt 1):1148-1167. doi:10.1111/j.1475-6773.2010.01130.x PubMedGoogle ScholarCrossref
8.
Silber  JH, Satopää  VA, Mukherjee  N,  et al.  Improving Medicare’s Hospital Compare Mortality Model.   Health Serv Res. 2016;51(suppl 2):1229-1247. doi:10.1111/1475-6773.12478PubMedGoogle ScholarCrossref
9.
Silber  JH, Rosenbaum  PR, Niknam  BA,  et al.  Comparing outcomes and costs of surgical patients treated at major teaching and nonteaching hospitals: a national matched analysis.   Ann Surg. 2020;271(3):412-421. doi:10.1097/SLA.0000000000003602 PubMedGoogle ScholarCrossref
10.
Elixhauser  A, Steiner  C, Harris  DR, Coffey  RM.  Comorbidity measures for use with administrative data.   Med Care. 1998;36(1):8-27. doi:10.1097/00005650-199801000-00004 PubMedGoogle ScholarCrossref
11.
Drye  EE, Normand  SL, Wang  Y,  et al.  Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling.   Ann Intern Med. 2012;156(1 Pt 1):19-26. doi:10.7326/0003-4819-156-1-201201030-00004 PubMedGoogle ScholarCrossref
12.
Normand  S-LT, Shahian  DM.  Statistical and clinical aspects of hospital outcomes profiling.   Stat Sci. 2007;22:206-226. doi:10.1214/088342307000000096 Google ScholarCrossref
13.
Bland  JM, Altman  DG.  Statistical methods for assessing agreement between two methods of clinical measurement.   Lancet. 1986;1(8476):307-310. doi:10.1016/S0140-6736(86)90837-8 PubMedGoogle ScholarCrossref
14.
R Core Team. R: a language and environment for statistical computing. Accessed December 12, 2020. http://www.R-project.org/.
15.
Gupta  S, Hayek  SS, Wang  W,  et al; STOP-COVID Investigators.  Factors associated with death in critically ill patients with coronavirus disease 2019 in the US.   JAMA Intern Med. 2020. doi:10.1001/jamainternmed.2020.3596 PubMedGoogle Scholar
16.
Horwitz  LI, Jones  SA, Cerfolio  RJ,  et al.  Trends in COVID-19 risk-adjusted mortality rates.   J Hosp Med. 2020. Published online October 23, 2020. doi:10.12788/jhm.3552PubMedGoogle Scholar
17.
US Food and Drug Administration. Veklury (remdesivir) EUA letter of approval. Accessed December 12, 2020. https://www.fda.gov/media/137564/download
18.
Spinner  CD, Gottlieb  RL, Criner  GJ,  et al; GS-US-540-5774 Investigators.  Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial.   JAMA. 2020;324(11):1048-1057. doi:10.1001/jama.2020.16349 PubMedGoogle ScholarCrossref
20.
Horby  P, Lim  WS, Emberson  JR,  et al; RECOVERY Collaborative Group.  Dexamethasone in hospitalized patients with covid-19—preliminary report.   N Engl J Med. 2020. doi:10.1101/2020.06.22.20137273 PubMedGoogle Scholar
21.
Gandhi  M, Rutherford  GW.  Facial masking for covid-19—potential for “variolation” as we await a vaccine.   N Engl J Med. 2020;383(18):e101. doi:10.1056/NEJMp2026913 PubMedGoogle Scholar
22.
Chassin  MR, Park  RE, Lohr  KN, Keesey  J, Brook  RH.  Differences among hospitals in Medicare patient mortality.   Health Serv Res. 1989;24(1):1-31.PubMedGoogle Scholar
23.
Jha  AK, Li  Z, Orav  EJ, Epstein  AM.  Care in US hospitals —the Hospital Quality Alliance program.   N Engl J Med. 2005;353(3):265-274. doi:10.1056/NEJMsa051249 PubMedGoogle ScholarCrossref
24.
Tsai  TC, Joynt  KE, Orav  EJ, Gawande  AA, Jha  AK.  Variation in surgical-readmission rates and quality of hospital care.   N Engl J Med. 2013;369(12):1134-1142. doi:10.1056/NEJMsa1303118 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    December 22, 2020

    Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic

    Author Affiliations
    • 1Division of General Internal Medicine, University of Pennsylvania, Philadelphia
    • 2Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
    • 3UnitedHealth Group, Minnetonka, Minnesota
    • 4Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia
    • 5Cpl Michael J. Crescenz VA Medical Center, Philadelphia, Pennsylvania
    JAMA Intern Med. 2021;181(4):471-478. doi:10.1001/jamainternmed.2020.8193
    Key Points

    Question  Are hospital outcomes for patients with coronavirus disease 2019 (COVID-19) improving?

    Findings  In this cohort study of 38 517 adults who were admitted with COVID-19 to 955 US hospitals, rates of 30-day mortality or referral to hospice varied from 9.06% to 15.65% in the best- and worst-performing quintiles. In the early months of the pandemic, 94% of hospitals in a subset of 398 improved by at least 25%, and the strongest determinant of improvements in hospital-level outcome was a decline in community rates of infection.

    Meaning  All else being equal, COVID-19 mortality in hospitals seems to be lower when the prevalence of COVID-19 in their surrounding communities is lower.

    Abstract

    Importance  It is unknown how much the mortality of patients with coronavirus disease 2019 (COVID-19) depends on the hospital that cares for them, and whether COVID-19 hospital mortality rates are improving.

    Objective  To identify variation in COVID-19 mortality rates and how those rates have changed over the first months of the pandemic.

    Design, Setting, and Participants  This cohort study assessed 38 517 adults who were admitted with COVID-19 to 955 US hospitals from January 1, 2020, to June 30, 2020, and a subset of 27 801 adults (72.2%) who were admitted to 398 of these hospitals that treated at least 10 patients with COVID-19 during 2 periods (January 1 to April 30, 2020, and May 1 to June 30, 2020).

    Exposures  Hospital characteristics, including size, the number of intensive care unit beds, academic and profit status, hospital setting, and regional characteristics, including COVID-19 case burden.

    Main Outcomes and Measures  The primary outcome was the hospital’s risk-standardized event rate (RSER) of 30-day in-hospital mortality or referral to hospice adjusted for patient-level characteristics, including demographic data, comorbidities, community or nursing facility admission source, and time since January 1, 2020. We examined whether hospital characteristics were associated with RSERs or their change over time.

    Results  The mean (SD) age among participants (18 888 men [49.0%]) was 70.2 (15.5) years. The mean (SD) hospital-level RSER for the 955 hospitals was 11.8% (2.5%). The mean RSER in the worst-performing quintile of hospitals was 15.65% compared with 9.06% in the best-performing quintile (absolute difference, 6.59 percentage points; 95% CI, 6.38%-6.80%; P < .001). Mean RSERs in all but 1 of the 398 hospitals improved; 376 (94%) improved by at least 25%. The overall mean (SD) RSER declined from 16.6% (4.0%) to 9.3% (2.1%). The absolute difference in rates of mortality or referral to hospice between the worst- and best-performing quintiles of hospitals decreased from 10.54 percentage points (95% CI, 10.03%-11.05%; P < .001) to 5.59 percentage points (95% CI, 5.33%-5.86%; P < .001). Higher county-level COVID-19 case rates were associated with worse RSERs, and case rate declines were associated with improvement in RSERs.

    Conclusions and Relevance  Over the first months of the pandemic, COVID-19 mortality rates in this cohort of US hospitals declined. Hospitals did better when the prevalence of COVID-19 in their surrounding communities was lower.

    ×